XORTX Therapeutics Inc.
XRTX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -53.53% | 90.09% | 79.69% | 51.15% | 72.04% |
| Total Depreciation and Amortization | -16.18% | -16.32% | -26.13% | -13.44% | 139.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 83.04% | -365.73% | -106.52% | 41.09% | -27.28% |
| Change in Net Operating Assets | 111.33% | 97.30% | 239.78% | -249.00% | -169.93% |
| Cash from Operations | 44.12% | 54.03% | 49.87% | 39.61% | 26.56% |
| Capital Expenditure | -- | 100.00% | 100.00% | 92.83% | 78.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 7.60% | -2.29% | 30.60% | 31.85% | -61.92% |
| Cash from Investing | 15.98% | 16.14% | 43.20% | 53.50% | -1.31% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -5.29% | -25.00% | -25.27% | -80.82% | -224.51% |
| Issuance of Common Stock | 1,172,266.67% | -59.66% | -59.66% | -59.66% | -99.99% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -126.18% | -431.23% | -119.92% | -112.73% | -9.53% |
| Cash from Financing | 869.73% | -73.47% | -70.84% | -70.89% | -107.67% |
| Foreign Exchange rate Adjustments | -978.05% | -71.43% | 84.57% | 96.51% | 103.01% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 86.06% | 27.20% | 27.40% | 9.56% | -57.51% |
